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Summary
 
Only mature B lymphocytes can enter the lymphoid follicles of spleen and lymph nodes and
thus efficiently participate in the immune response. Mature, long-lived B lymphocytes derive
from short-lived precursors generated in the bone marrow. We show that selection into the
mature pool is an active process and takes place in the spleen. Two populations of splenic B
cells were identified as precursors for mature B cells. Transitional B cells of type 1 (T1) are re-
cent immigrants from the bone marrow. They develop into the transitional B cells of type 2
(T2), which are cycling and found exclusively in the primary follicles of the spleen. Mature B
cells can be generated from T1 or T2 B cells.
Mice with genetic deletions of elements participating in the B cell receptor signaling cascade
display developmental arrest at the T1 or T2 stage. The analysis of these defects showed that
the development of T2 and mature B cells from T1 precursors requires defined qualitative and
quantitative signals derived from the B cell receptor and that the induction of longevity and
maturation requires different signals.
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I
 
n the adult mouse, B cells are generated in the bone mar-
row. Their development requires the successful rearrange-
ment of the Ig H and L chain gene loci and the surface ex-
pression of the B cell antigen receptor (BCR)
 
1
 
 (1).
The BCR is composed of the membrane-bound Ig mol-
ecule and the Ig-
 
a
 
/Ig-
 
b
 
 heterodimer. The Ig-
 
a
 
/Ig-
 
b
 
 het-
erodimer is indispensable for the surface expression and
signaling function of the BCR (2). In the early phases of
development in the bone marrow, B cells only express
IgM. Immature B cells have a low density of IgM (IgM
 
dull
 
)
and are still resident in the parenchyma of the bone mar-
row. They develop into IgM
 
bright
 
 transitional B cells (3) and
move toward and through the bone marrow sinusoids be-
fore migrating to the periphery (4). Few of the transitional
B cells enter the mature, long-lived B cell compartment.
Out of the 2 
 
3
 
 10
 
7
 
 IgM
 
1
 
 B cells that develop daily in the
bone marrow of the mouse, 10% reach the spleen and only
1–3% enter the mature B cell pool (5, 6). Mature B cells
coexpress IgM and IgD (7). IgM
 
1
 
IgD
 
1
 
 B cells in the bone
marrow are thought to be B cells that have completed their
maturation process in the periphery and return to the bone
marrow as mature recirculating B cells. In the normal
mouse, only mature B cells are long lived, can recirculate
with the lymph and the blood, and are able to enter the
lymphoid follicles of spleen and lymph nodes. These abili-
ties are very important to mount an efficient immune re-
sponse. Only B cells that can enter the follicle have access
to antigen deposited on the follicular dendritic cells and are
able to initiate the germinal center reaction and then rap-
idly produce antigen-specific, high-affinity Abs.
The rules that regulate the size, diversity, and quality of
the long-lived B cell pool are therefore important but largely
unknown. It is, however, likely that signals from the BCR
control these differentiation events (8–11). Indeed, mice with
 
1
 
Abbreviations used in this paper:
 
 BCR, B cell antigen receptor; BrdU, bro-
modeoxyuridine; Btk, Bruton’s tyrosine kinase; HSA, heat-stable antigen;
MAP, mitogen-activated protein; MZ, marginal zone; PALS, periarterio-
lar lymphoid sheath; PH, plekstrin homology; PKC, protein kinase C;
T1, transitional type 1; T2, transitional type 2. 
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natural or targeted deletions or mutations of genes encoding
elements involved in BCR signaling often show abnormal
development of B cells and are therefore useful tools to study
the molecular requirements for lymphocyte differentiation.
The deletion of the cytoplasmic part of Ig-
 
a
 
 in mb1 
 
D
 
c/
 
D
 
c
mice (12) still permits expression of the IgM-BCR on the
cell surface, and B cell development in the bone marrow is
compromised but not completely blocked. However, the
mature B cell pool is absent in the periphery.
CD45 is a tyrosine phosphatase expressed in alternatively
spliced forms on the surface of B and T cells and cells of
the myeloid lineage. In mice deficient for CD45 (13), thy-
mocyte development is blocked at the CD4, CD8 double-
positive stage. The early stages of B cell differentiation in
the bone marrow are normal, but B cell development is
blocked in the spleen (14). CD45 positively regulates BCR
signaling. In B cells deficient for CD45, BCR cross-linking
fails to elicit calcium influxes from the extracellular space
and induce B cell proliferation (14). These defects can be
explained at least partially by the positive regulatory role
that CD45 exerts on the Src family kinase Lyn. Lyn plays a
fundamental role in BCR signaling (15).
Bruton’s tyrosine kinase (Btk) is a 77-kD nonreceptor
tyrosine kinase that is specifically expressed in myeloid cells
and B lymphocytes (16). Btk plays a complex role in BCR
signaling. It is rapidly activated by Src family kinases after
BCR cross-linking and interacts with a number of ligands
participating in the BCR signaling cascade. Btk has an
NH
 
2
 
-terminal plekstrin homology (PH) domain that inter-
acts with the PI-3 kinase product phosphatidylinositol
(3,4,5) triphosphate (PI[3,4,5]P
 
3
 
) and with other signaling
molecules, like protein kinase C (PKC) (17) and G proteins
(18). The interaction with PI(3,4,5)P
 
3
 
 regulates the recruit-
ment of Btk to the cell membrane and thus the intensity and
duration of extracellular calcium fluxes (19). The localization
of Btk to the cell membrane might also be influenced by the
interaction with PKC. PKC activity, in turn, is modulated
by Btk. The association with G protein results in an increase
of the catalytic activity of Btk (20). The PH domain is essen-
tial for the function of Btk. CBA/N mice, which represent
the prototype for the murine X-linked immunodeficiency
(xid), have a mutation (Arg28
 
®
 
Cys) in the PH domain (21).
B cell development is blocked at an immature stage in the
spleens of CBA/N mice (22); the same defect is observed in
mice with a complete deletion of the Btk domain (23).
We have analyzed the late stages of B cell development
in normal mice and in mice with mutations of Ig-
 
a
 
, CD45,
and Btk, elements that all participate in the transduction of
signals from the BCR. We confirm that specific signals de-
rived from the BCR are indispensable for the survival of B
cells that have just left the bone marrow and demonstrate
that the quality of these signals regulates their further differ-
entiation into mature, long-lived B cells.
 
Materials and Methods
 
Mouse Strains.
 
CD45
 
2
 
/
 
2
 
 
 
(13) and RAG-2
 
2
 
/
 
2
 
 
 
(24) mice have
been described before (13, 21). Mutant mice and mice of stan-
 
dard strains (C57BL/6, CBA/J, and CBA/N) were bred and
maintained in our animal facilities, with the exception of the mb1
 
D
 
c/
 
D
 
c–deficient (12) and the mb1 
 
D
 
c/
 
D
 
c-CD45
 
2
 
/
 
2
 
 
 
double-
mutant mice, which were bred at the Basel Institute of Immu-
nology (Basel, Switzerland). Adult mice were 6–8 wk old.
 
Flow Cytometry.
 
Single-cell suspensions, prepared from dif-
ferent organs, or peripheral blood samples were depleted of
erythrocytes by lysis with Gey’s solution. For three-color fluores-
cence surface staining, 10
 
6
 
 cells per sample were incubated with
varying combinations of FITC-, PE-, Cy5-, and biotin-labeled
Abs. Streptavidin–RED670 (GIBCO BRL) was used as second-
step reagent. Apoptotic cells were detected using merocyanine
540 (Sigma Chemical Co.) at 1 
 
m
 
g/ml. Data was collected on a
FACScan™ or FACStar
 
PLUS™
 
 flow cytometer (Becton Dickin-
son) and analyzed using CELLQuest™ software (Becton Dickin-
son). The following mAbs were used: anti-IgM (clone 2911),
anti-IgD (clone 11.26c), anti-CD21 (clones 7G6 and 7E9), anti-
CD23 (clone B3B4), anti-B220 (clone RA3-6B2), and anti-HSA
(heat-stable antigen; clone M1/69). They were prepared and labeled
in our laboratory or purchased from PharMingen. PE-labeled goat
F(Ab)
 
2
 
 anti–IgM was purchased from Caltag Labs., and Cy5-labeled
goat anti–IgM was from Jackson ImmunoResearch Labs., Inc.
 
Bromodeoxyuridine Labeling and Cell Cycle Analysis.
 
The thymi-
dine analogue bromodeoxyuridine (BrdU; 1 mg/ml) was freshly
prepared every day and administered in the mouse drinking wa-
ter. Normal water was given after a 3–5-d labeling period. BrdU
incorporated into the DNA during the application period was
detected by flow cytometry, using a protocol that allowed both
examination of BrdU incorporation and surface phenotype (6).
At each point of measurement, two mice per experimental group
were analyzed. Anti-BrdU Abs were purchased from Becton
Dickinson and BrdU from Calbiochem Corp.
For cell cycle analysis, splenic and bone marrow cells were first
stained with FITC- and CY5-labeled Abs directed against surface
markers. Cells were then fixed with 70% ethanol. Propidium iodide
(10 
 
m
 
g/ml) was added after a 30-min treatment with RNase.
 
Transfer Experiments.
 
Splenic cells from a pool of 8 and, in a
second experiment, 20 1-wk-old C57BL/6 mice were depleted
of erythrocytes and dead cells by density gradient centrifugation
(Ficoll Paque; Pharmacia Biotech). The percentage of transitional
type 1 (T1) B cells in the preparation was measured by flow cy-
tometry. Cells were injected into the tail veins of adult RAG-2
 
2
 
/
 
2
 
mice in 200 
 
m
 
l PBS. Each mouse received 2 
 
3
 
 10
 
6
 
 B cells.
Sorted transitional type 2 (T2) cells (10
 
6
 
) were injected into
the tail veins of adult RAG-2
 
2
 
/
 
2
 
 mice. The spleens of recipient
mice were analyzed by flow cytometry after 24 and 48 h. Three
independent experiments were performed.
 
Histology.
 
Cryostatic sections (6 
 
m
 
m) of spleens were fixed with
cold acetone and then stained with fluorescent Abs. Slides were ana-
lyzed with a Leica Confocal Laser Scanning Microscope (model
TCS 4D). For FITC, the excitation wavelength was 488 nm, and
the emitted fluorescence was collected with a BP 520 filter. TRITC
was excited at 568 nm and fluorescence was collected with an LP
590 filter. TRITC-labeled IgM was from Jackson ImmunoResearch
Labs., Inc. and anti-MAdCAM was from PharMingen.
 
Results
 
Transitional B Cells of Normal Mice Can Be Separated into Two
Subsets, T1 and T2, Based on Expression of IgD and CD21.
 
We have recently described an intermediate stage in the de-
velopment of B cells in the bone marrow, the transitional B 
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cell stage (3), and we have shown, as later studies have con-
firmed (25), that transitional B cells are the target of negative
selection. Transitional B cells express high amounts of IgM
(IgM
 
bright
 
) and low amounts of IgD (IgD
 
dull
 
). Based on the
surface expression of IgM and IgD, transitional B cells (indi-
cated as T in Fig. 1 A) can be distinguished from IgM
 
dull
 
IgD
 
2
 
immature B cells and from IgM
 
dull
 
IgD
 
bright 
 
mature B cells
(Fig. 1 A, indicated by M; prototypic mature B cells are
lymph node B cells). Transitional B cells are found not only
in the bone marrow but also in the blood and spleen (Fig.
1 A, top panels). In the bone marrow, 15–20% of all B lym-
phocytes have the phenotype of transitional B cells, whereas
in the blood they are 15–20% and in the spleen 10–15% of all
B cells. In the lymph node, transitional B cells are not found.
Figure 1. Transitional B cells of
normal mice. Three-color flow cy-
tometric analysis of cells isolated
from bone marrow, blood, spleens,
and lymph nodes of adult C57BL/6
mice. 100,000 events were col-
lected. (A) Log density plots show-
ing IgD and IgM expression. Top,
all cells; center, MEL-142 cells;
bottom, MEL-141  cells. M, ma-
ture B cells; T, transitional B cells.
Arrows, cells that are indicated as
T2 in panel B. (B) Cells were
stained with Abs to IgM and
CD21. M, mature B cells; T1,
CD212  and T2, CD21bright transi-
tional B cells. (C) Splenocytes were
stained with Abs to IgM, IgD, and
CD23. The plots show the IgD and
IgM staining of cells separated on
the basis of the expression of CD23.
CD232 B cells include IgMbright
IgD2 T1, and MZ B cells and all
IgM2 cells in the spleen (T cells and
macrophages). Only B cells are pos-
itive for CD23. They are mostly T2
and mature (M) B cells. (D) Sple-
nocytes were stained with Abs to
IgD, CD21, and IgM and separated
into IgD2 or IgD1 cells. IgD2 T1
and MZ B cells can be distin-
guished on the basis of CD21 ex-
pression. T2 and mature B cells are
both in the gate of the IgD1 B cells
but are either bright (T2) or dull
(M) for IgM. 
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Lymphocyte entry in the lymph nodes is dependent on
 
l
 
-selectin, an adhesion molecule that facilitates migration
through the high endothelial venules (26). We used the
anti–
 
l
 
-selectin Ab MEL-14 to separate bone marrow, blood,
spleen, and lymph node cells in MEL-14
 
2
 
 and MEL-14
 
1
 
cells (Fig. 1 A, center and bottom panels, respectively).
Transitional B cells were exclusively MEL-14
 
2
 
 (Fig. 1 A,
center panels, gate T). Mature B cells were instead almost
all positive for MEL-14. Only a minor fraction (
 
,
 
10%) of
the mature B cells in the spleen and lymph node was nega-
tive for MEL-14. Our analysis suggests that transitional B
cells leave the bone marrow with the blood. The absence
of 
 
l
 
-selectin on transitional B cells is consistent with their
inability to enter the lymph node and their preferential mi-
gration to the spleen. A second population of IgM
 
bright 
 
B
cells is found exclusively in the spleen and expresses, in
contrast to transitional B cells, both IgD and 
 
l
 
-selectin (Fig.
1 A, arrows). We have used CD21 as a marker to further
analyze this population. CD21, or complement receptor
type 2 (CR-2), binds to C3 complement components (27)
and is expressed in a developmentally regulated way. It is
not present on immature B cells but is expressed on mature
B cells. By staining with Abs to IgM and CD21, we could
divide the
 
 
 
population of IgM
 
bright
 
 B cells into two popula-
tions, which we have called transitional 1 (T1) and transi-
tional 2 (T2). T1 B cells lack CD21, whereas T2 B cells
express CD21 in higher amounts (CD21
 
bright
 
) than mature
B cells (Fig. 1 B). T2 B cells are found exclusively in the
spleen but not in the bone marrow, blood, or lymph node
(Fig. 1 B).
Figure 2. T1 B cells are the precursors of T2 and mature B cells. (A) Splenocytes of 1- (left) and 3- (center) wk-old and adult (right) C57BL/6 mice
were stained with Abs to CD21 and IgM and analyzed by flow cytometry. (B) Splenic cells from recipient RAG-22/2 mice were analyzed at the indicated
times after transfer of 2 3 106 splenic B cells from a pool of 1-wk-old mice. Cells were stained with Abs to IgM, IgD, and CD21. Top panels, IgM vs. IgD
staining. Bottom panels, the CD21 vs. IgM profile of IgD1IgM1 donor B cells. 200,000 events were collected. Data is shown as dot plots to highlight the
few transferred cells that home to the spleen. In the dot plots corresponding to the control (adult) spleen, only 5% of the collected events are shown. 
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Relationship of T2 B Cells to Previously Described B Cell
Populations.
 
Recently, CD21
 
bright
 
IgM
 
bright
 
 B cells in the
spleen have been identified as marginal zone (MZ) B cells
(28). The MZ is mainly populated by B cells and macro-
phages and surrounds the lymphoid follicle outside the
marginal sinus. MZ B cells do not express the differentia-
tion markers IgD and CD23, which are also absent on im-
mature and transitional B cells in the bone marrow (3).
Splenic CD23
 
2
 
 B cells are IgM
 
bright
 
 and IgD
 
2
 
 (Fig. 1 C,
left), whereas CD23
 
1
 
 B cells coexpress IgM and IgD (Fig.
1 C, right). A more precise discrimination of the different
B cell populations in the spleen is based on comparing the
expression of CD21 and IgM on IgD
 
2
 
 or IgD
 
1
 
 B cells
(Fig. 1 D). IgM
 
bright
 
IgD
 
2
 
 B cells include T1 B cells, which
are CD21
 
2
 
, and MZ B cells, which are CD21
 
bright
 
 (Fig. 1 D,
left). IgM
 
1
 
IgD1 B cells include T2 and mature B cells (Fig.
1 D, right). Therefore, we can identify two populations of
IgMbrightCD21bright B cells in the spleen: (i) the MZ B cells
(3–5% of the splenic B cells), which lack IgD and CD23
and (ii) T2 B cells (15–20%), which express both IgD and
CD23. T1 B cells represent 5–10% of splenic B cells, with
mature B cells corresponding to the remainder.
T2 cells thus represent a distinct population of IgMbright
IgDbrightCD21brightCD231 B cells. This phenotype distin-
guishes them from T1, MZ, and mature B cells. Moreover,
they are found exclusively in the spleen and not in the lymph
node or bone marrow. We found T2 B cells in the spleens of
adult mice of different genetic backgrounds (C57BL/6,
BALB/c, CBA/J, or NMRI), independent of intentional
immunization or housing conditions (conventional, specific
pathogen free, and germ free; results not shown).
T1 B Cells Are the Precursors of T2 and Mature B Cells.
To investigate the developmental relationship between T1,
T2, and mature B cells, we studied their distribution among
splenocytes of mice at various ages. In the adult mouse, T1,
T2, and mature B cells were present in the expected pro-
portions (Fig. 2 A, right). In the spleens of 1-wk-old mice,
all B cells were T1 B cells (Fig. 2 A, left). T2 and mature B
cells started to appear at 2 wk of age (not shown) and were
clearly detectable in the spleen of 3-wk-old mice (Fig. 2 A,
center). At this time, the T1 population was still larger than
in the adult mice (40%), and the fractions of T2 and mature
B cells were reduced. MZ B cells are not present in the
spleens of newborn mice; they are first detectable in the
spleen at 4 wk of age (28).
To study the developmental potential of neonatal T1 B
cells, we transferred splenocytes from 1-wk-old mice into
adult RAG-22/2 mice, which lack B and T cells (24). Do-
nor splenocytes were injected into the mouse tail veins, and
the spleens of recipient mice were analyzed 5, 24, and 48 h
after transfer. The expression patterns of IgD and IgM
showed that 5 h after transfer, all donor B cells still had the
T1 phenotype (Fig. 2 B, top). IgD1 and IgMdull cells were
found 24 h after transfer (Fig. 2 B, top). Mature B cells and
T2 B cells were clearly detectable after 48 h (Fig. 2 B, top,
labeled M and T2, respectively). This was confirmed by the
analysis of CD21 expression on B cells (B cells were de-
fined as being positive for IgM and/or IgD). In Fig. 2 B,
bottom, the expression patterns of CD21 and IgM are rep-
resented. 48 h after transfer, T2 B cells were 52% of all B
cells, whereas mature B cells were 36% (Fig. 2 B, bottom).
Both T2 and mature B cells expressed CD23 (not shown).
In a second experiment, the fate of transferred cells was fol-
lowed for 7 d after injection. At this time, mature and T2 B
cells were still detectable, but z50% of the transferred cells
had downregulated IgD and CD23 and could be consid-
ered phenotypically MZ B cells (not shown). In both ex-
periments, the transferred cells constituted z1% of all sple-
nocytes of recipient mice.
These experiments demonstrate that in the adult spleen,
neonatal T1 B cells develop to T2 and mature B cells in 2 d
and to MZ B cells in 7 d. Therefore, neonatal T1 B cells do
not have an intrinsic defect that prevents their further mat-
uration (29) but most likely, the microenvironment of the
neonatal spleen does not support the late phases of B cell
development, from T1 to T2 and to mature B cells.
Figure 3. T2 B cells develop into mature B cells in the spleen. (A)
Spleen cells of adult mice were stained with Abs to HSA and CD21, and
T1, T2, and mature (M) B cells were identified (before sort).
CD211HSAbright T2 B cells were sorted (after sort) and transferred into
adult RAG-22/2 recipient mice. (B) The spleens of recipient RAG-22/2
mice were analyzed 24 h after transfer and compared with the spleen of
an adult control mouse. T1, T2, and mature B cells were identified on the
basis of the expression of HSA, B220, IgM, and IgD. The plots show the
IgD and IgM staining of cells that were positive for B220 and either
bright or dull for HSA.80 B Cell Development in the Spleen
T2 B Cells Develop into Mature B Cells. What is the de-
velopmental relationship between T2 and mature B cells?
T2 and mature B cells could independently develop from
the T1 population, or T2 B cells could represent an inter-
mediate stage of development, preceding the mature stage.
To address this question, we isolated T2 B cells from the
spleen of a normal adult mouse, transferred them into
RAG-22/2 mice, and analyzed their developmental poten-
tial. To separate T2 from T1 and mature B cells, we did
not use the IgM and IgD antigen receptors as markers, be-
cause the staining procedure could have initiated BCR-
mediated signals and, therefore, influenced B cell survival
and differentiation. T1, T2, and mature B cells were in-
stead identified on the basis of their expression of HSA and
CD21. The expression of HSA is developmentally regu-
lated in B cells. It is high in early phases of development in
the bone marrow, and it is downregulated in mature B cells.
Recent bone marrow immigrant B cells express higher
amounts of HSA than mature B cells (5). By staining with
Abs to HSA and CD21, we could distinguish T1, T2, and
mature B cells. T1 B cells are HSAbright and lack CD21. T2
B cells are also HSAbright but express CD21, and mature B
cells are HSAdull and CD211 (Fig. 3 A, before sort). In fur-
ther experiments, we confirmed the accuracy of the dis-
crimination by using IgM and IgD as additional markers
(not shown). The purity of sorted T2 B cells (Fig. 3 A, after
sort) was also controlled by staining an aliquot with Abs to
IgM and IgD. Sorted T2 B cells expressed high amounts of
both IgM and IgD and, therefore, corresponded to bona
fide T2 B cells.
106 sorted HSAbrightCD211 T2 B cells were injected into
the tail veins of RAG-22/2 mice. Recipient mice were
killed 24 h later, and splenocytes were stained with Abs to
B220, HSA, IgD, and IgM. As control, a normal mouse
was analyzed; the staining pattern of T1 and T2 B cells is
shown in Fig. 3 B (control). Both populations were unde-
tectable in the mice that had received the T2 transplant. At
least 95% of the B cells isolated from host RAG-22/2
spleens were B2201HSAdull mature B cells (Fig. 3 B, 24 h).
Three independent experiments were performed, and re-
cipient mice were also analyzed 48 h after transplantation,
always with comparable results (not shown).
Our experiments demonstrate that T2 B cells develop
into mature B cells in the spleen. This step of differentia-
tion is associated to the downregulation of IgM and HSA.
Our data does not exclude the possibility that at least a frac-
tion of the T1 B cells can also directly develop into mature
B cells.
T2 B Cells Are in the Primary Follicle. To study the lo-
calization of T1, T2, and mature B cells in the spleens of
normal mice, we stained sections with TRITC-coupled Abs
to IgM and with FITC-coupled Abs to IgD (Fig. 4 A).
IgMbrightIgD2 MZ and T1 B cells appear in red, T2 B cells,
which coexpress high amounts of IgM and IgD, appear in
yellow, and mature B cells, which are bright for IgD and
have downregulated IgM, are green (Fig. 4). T1 B cells are
in the outer periarteriolar lymphoid sheet (PALS) close to
the primary follicle. T2 and mature B cells are together in-
side the follicle. Mature B cells can also be seen in the outer
PALS and in the red pulp. MZ B cells, as expected, sur-
Figure 4. T2 B cells are in the primary follicle of normal mice. (A) Sections of normal spleen were fixed and stained with TRITC-labeled goat anti–mouse
IgM and FITC-labeled anti-mouse IgD. Green and red fluorescence were measured separately by confocal laser microscopy, and the pictures obtained were
then overlaid (magnification 100). M, mature B cells. (B) The sector indicated by the square in A was scanned with a 250-fold amplification to better visual-
ize single cells. T1 B cells (red) are indicated by the single-headed arrow and T2 (yellow) by the double-headed arrow. Mature B cells are green.81 Loder et al.
round the follicle. Fig. 4 B shows an enlargement of the
bordering area between outer PALS and follicle, where
single T1 (red; indicated by the single-headed arrow) and
T2 cells (yellow; indicated by the double-headed arrow)
can be seen, together with mature B cells (bright green).
B Cell Development Is Arrested at the T2 B Cell Stage in the
Spleens of CD452/2 and CBA/N Mice. Development of
mature B cells is compromised in mice deficient for CD45
and in mice mutant for Btk (CBA/N). We stained spleno-
cytes of normal control, CD452/2, and CBA/N mice with
Abs to IgM, IgD, CD21, and CD23. Most of the splenic B
cells of CD452/2 and CBA/N mice are phenotypically
identical to the T2 B cells of normal mice. They are IgMbright
IgDbright (Fig. 5 A, gate T2) and CD231CD21bright (Fig.
5 B, bottom panels). T2 B cells, however, are present in a
higher percentage: in CD452/2 mice, they represent 49%
and in CBA/N mice 44% of all B cells, as compared with
15–20% in normal mice. The fraction of T1 B cells is only
slightly reduced in size in CD452/2 mice and is normal in
CBA/N mice.
Surprisingly, MZ B cells are present in the expected pro-
portions and have a normal phenotype in CD45 and CBA/N
mutant mice. We calculated the percentages of T1, T2,
and MZ B cells in normal and mutant mice based on the
stainings shown in Fig. 5 B. In normal mice, T1 B cells
(IgMbrightCD232CD212) represent 7% and MZ B cells
(IgMbrightCD232CD211) 3% of all B cells. The fraction of
T1 B cells is slightly reduced in the CD452/2 spleen (4%);
the fraction of MZ B cells is normal (3%). In the CBA/N
mouse, both T1 and MZ B cells are slightly increased in
percentage (13 and 5%, respectively). Prototypic mature B
cells are not found in these mice: the cells in gate M (ma-
ture) in Fig. 5 express more IgM and CD21 than normal
mature B cells.
The genetic background does not influence the distribu-
tion of T1, T2, and mature cells in the spleen, because the
relative size and phenotype of the three populations is
identical in normal C57BL/6 and CBA/J mice, which are
genetically matched controls for CD452/2 and CBA/N
mice, respectively (not shown). Therefore, in all of the fol-
lowing experiments, we used C57BL/6 mice as controls.
Although the frequency of T2 B cells is similarly in-
creased in CD452/2 and CBA/N mice, their absolute
number is dramatically different in the two mutant mice. In
Figure 5. B cell development is blocked at the
T2 stage in CD452/2 and CBA/N mice, but the
number and the phenotype of MZ B cells is nor-
mal. Flow cytometric analysis of splenic B cells
from normal C57BL/6 (control) and CD452/2 and
CBA/N mice. (A) Cells were stained with Abs to
IgM and IgD. T1, T2, and mature (M) B cells are
boxed. (B) Cells were stained with Abs to CD23,
CD21, and IgM and separated into CD232 and
CD231 cells. T1, T2, MZ, and mature B cells were
identified as in Fig. 1 C. The fraction of T2 B cells
represented 23% of all B cells in the normal mouse
spleen, 55% in the CD452/2 spleen, and 50% in the
CBA/N spleen.82 B Cell Development in the Spleen
the spleens of CD452/2 mice, the absolute number of T2
B cells is six to eight times larger than in control mice,
whereas in CBA/N mice, the size of the T2 population is
normal (Fig. 6). In contrast, the total number of the pheno-
typically aberrant mature B cells is reduced in the CBA/N
mice but normal in CD452/2 mice. These data demon-
strate that the defect in B cell development that leads to an
arrest at the T2 stage is not identical in the two mutant
mice. To support this conclusion, we backcrossed CD452/2
to CBA/N mice. In double-mutant mice, the number of
T2 B cells is five times higher and the number of mature B
cells is four times lower than in normal mice (Fig. 6). These
results prove that CD45 plays a role in determining the
number of cells in the T2 B cell pool, whereas Btk either
facilitates the entry of T2 B cells into the mature B cell
pool or prolongs the survival of mature B cells.
T2 B Cells Proliferate in the Spleen; Proliferation Is Deregu-
lated in CD452/2 Mice. In normal mice, mature B cells
are long lived, and recent splenic immigrant B cells from
the bone marrow are short lived, with a life span of 3 d af-
ter their arrival in the spleen. Subsequently, they are either
incorporated into the long-lived pool or eliminated (5, 30).
We determined the frequency and phenotypic distribution
of short- and long-lived B cells in CD45 and Btk mutant
mice using the BrdU labeling technique. Mice were ana-
lyzed 24, 72, and 120 h after the onset of the treatment. 24 h
after the beginning of the BrdU administration, the frac-
tion of labeled cells was 4% in the spleens of normal mice
(Fig. 7) and rose to a maximal 16% after 3 d of continuous
treatment. In CD452/2 and CBA/N mice, about half of
the splenic B cells incorporated BrdU in 24 h. The per-
centage of labeled cells remained constant thereafter. Our
results confirm the life span analysis of splenic B cells of
normal mice but indicate that in mutant mice, labeled B
cells have a life span of only 1 d.
Splenic B cells that are labeled after a short BrdU pulse
represent the balance of (a) cells derived from cycling bone
marrow precursors, (b) labeled cells that died during the
treatment period, and (c) cells that entered the cell cycle in
the spleen. This last factor is not considered significant in
the normal mouse. However, because B cell numbers and
labeling rates were normal in the bone marrow of CD452/2
mice (not shown), the large number of B cells labeled with
BrdU can only be explained by proliferation in the spleen.
Therefore, we studied cell cycle progression of T1, T2,
and mature B cells in spleen and bone marrow. The differ-
ent populations were identified by surface staining with
anti-IgM and anti-CD21 Abs, and DNA content was mea-
sured with propidium iodide. As expected, in spleens and
bone marrow of normal and mutant mice, 93–97% of the
mature and T1 B cells are in the G0–G1 phase of the cell cy-
cle (Table I). Surprisingly, 15% of the T2 B cells of normal
mice are in the G2–M phase of the cell cycle. In CD452/2
mice, 33% and in CBA/N mice, 21% of the T2 B cells are in
the G2–M phase. In this type of analysis, MZ B cells are in-
cluded in the T2 B cell population. Although they represent
a minor fraction, we have also measured cell cycle progres-
sion in IgMbrightIgDbright (proper T2 B cells), IgMbrightIgD2
(T1 and MZ B cells), and IgM1IgDbright cells (mature B
cells). The results confirmed the notion that T1, MZ, and
mature B cells are noncycling cells, whereas the T2 B cells
are a population of cycling cells (Table I, bottom). There-
fore, entrance into the cell cycle appears to be a normal
event at the T2 B cell stage, but proliferation is limited. In
contrast, proliferation is deregulated in the absence of CD45.
Entrance into the Mature Pool Is Impaired in CBA/N Mice.
The recruitment rate into the long-lived pool was mea-
sured by pulse–chase experiments. The fraction of BrdU-
labeled B cells was measured 18 d after a 3-d labeling pulse
with BrdU. As few as 14% of the B cells that had incorpo-
rated BrdU over a 3-d period entered the long-lived pool
in the spleens of normal mice, compared with an even
lower 2% in CD452/2 and 2% in CBA/N mice (Fig. 7).
Therefore, the number of splenic B cells labeled after 3 d of
continuous BrdU administration corresponds to the number
Figure 6. Absolute number of
T2 and mature (M) splenic B
cells in normal, CD452/2, and
CBA/N and in CD452/2CBA/N
double-mutant mice. Cell num-
bers were calculated using the
gates shown in Fig. 5. Stippled
bar, normal; gray bar, CD452/2;
black bar, CBA/N; hatched bar,
double mutant.
Figure 7. Kinetics of BrdU labeling of B lymphocytes of normal and
mutant mice. Mice received BrdU (1 mg/ml) in their drinking water for
the indicated times. Splenic B cell populations were identified on the basis
of three different surface staining protocols: IgM vs. IgD, IgM vs. CD21,
and IgD vs. CD22. The BrdU content of the cells was determined by
flow cytometry. The experiments were repeated three times, and compa-
rable results were obtained. The columns represent the percentages of
BrdU-labeled B cells in normal and mutant mice analyzed 24 (stippled
bars) and 72 h (gray bars) after the beginning of the BrdU administration.
The percentage of B cells still labeled 18 d after a 3-d treatment with
BrdU (18-d chase; black bars) is also shown. The absolute numbers of la-
beled B cells in the normal spleen were 2 3 106 after 24 h, 5.6 3 106 after
3 d, and 0.9 3 106 after the 18-d chase. In the CD452/2 mouse, 35 3
106 B cells were labeled after 24 h and 37.8 3 106 after 3 d. 0.8 3 106 B
cells were still labeled after the 18-d chase. The CBA/N mouse had 2.4 3
106 labeled B cells on day 1 and 3.2 3 106 on day 3. Only 0.1 3 106 cells
were still labeled after the chase.83 Loder et al.
of short-lived B cells, whereas long-lived B cells are mostly
unlabeled. The absolute numbers of these cell populations
in the spleen are given in Table II. We also calculated the
number of labeled B cells that were still detectable 18 d af-
ter the BrdU pulse and that, as we have seen, correspond to
the small percentage of short-lived B cells that were re-
cruited into the long-lived pool. In CBA/N mice, the
number of short-lived splenic B cells was identical to the
number in control mice, but in CD452/2 mice, it was sev-
enfold higher. The total number of long-lived cells is nor-
mal in CD45 mutant mice but reduced sixfold in CBA/N
mice. Accordingly, the number of B cells that entered the
long-lived pool was significantly reduced in CBA/N mice
but normal in CD452/2 mice (Table II).
The short life span of a major part of B cells in the mu-
tant mice and the low fraction of cells that enter the long-
lived pool implies that the death rate is very high among
these cells. We measured the fraction of apoptotic cells in
normal and mutant mice with merocyanine 540, a pigment
that binds to the membranes of cells in the early phases of
the apoptotic process (31, 32). Whereas only 10% of the
T2 B cells bound merocyanine in the normal spleen, 30%
of them were apoptotic in CD452/2 mice and 25% were
apoptotic in CBA/N mice (data not shown).
In conclusion, BrdU labeling experiments and cell cycle
analysis confirm that the defects in CD452/2 and CBA/N
mice are not identical. In CD452/2 mice, B cells extensively
proliferate at the T2 stage in the spleen, but the number of
long-lived B cells is normal. In CBA/N mice, the apparent
increase of T2 B cells is due instead to the reduction of the
long-lived mature B cells. In addition, in both mutant mice,
long-lived B cells had an abnormal phenotype, showing that
the ability to survive can be dissociated from the phenotype
in mutant B cells.
The BCR Is Indispensable for the Development of T2 and
Mature B Cells. It has been suggested that B cells are se-
lected into the mature B cell pool by antigen (8–11). Selec-
tion, therefore, would depend on the engagement of the
BCR. To analyze the role of the BCR in the development
of T1, T2, and mature B cells, we analyzed the late stages
of B cell development in mb1 Dc/Dc mice (12). These
mice have a complete deletion of the cytoplasmic tail of
the Ig-a component of the BCR, which causes a severe
block in the development of peripheral B cells (12). In the
spleens of these mice, the number of T1 B cells is 20% of
normal, but T2, mature, and MZ B cells are undetectable
(Fig. 8, left). This finding confirms that the signaling func-
tion of the BCR is essential for the development of T2,
mature, and MZ B cells from T1 B cells.
To prove that development of T2 B cells requires signal-
ing through the BCR, we backcrossed CD452/2 to mb1/
Dc/Dc mice. In double-deficient mice, the enlarged T2
Table I. Cell Cycle Analysis of T1, T2, and Mature B Cells
Mature T1 T2 and MZ
Control
spleen 3 3 15
bone marrow 5 5 —
CD45
spleen 3 2 33
bone marrow 5 3 —
CBA/N spleen 4 3 21
bone marrow 7 5 —
Mature T1 and MZ T2
Control spleen 3 1 17
CD45 spleen 4 1 31
CBA/N spleen 4 4 31
Top: spleen and bone marrow cells were stained with Abs to IgM and
CD21. After ethanol fixation, propidium iodide was used to label
DNA. For cell cycle analysis, cells were gated in T1, T2, and M, as in-
dicated in Fig. 1 B, and the DNA content was measured in these sub-
populations. In bone marrow, T2 B cells are undetectable. Percentages
of B cells in the G2–M phase of the cell cycle are given.
Bottom: splenic cells were stained with Abs to IgM and IgD before
DNA labeling. T1, MZ, T2, and mature B cells were identified as de-
scribed in the text.
Table II. Absolute and Relative Numbers of Short- and Long-lived 
B Cells in the Spleens of Normal and Mutant Mice
Short-lived Long-lived Short®long-lived
Control 5.6 (100%) 29.4 (100%) 0.9 (100%)
CD452/2 37.8 (670%) 46.2 (157%) 0.8 (89%)
CBA/N 5.2 (92%) 4.8 (16%) 0.1 (11%)
The absolute number (3 106) of labeled (short-lived) and unlabeled
(long-lived) B cells in the spleens of control, CD452/2, and CBA/N
mice was calculated after 3 d of continuous treatment with BrdU. The
number of labeled B cells detected 18 d after the 3-d BrdU treatment
period corresponds to the number of B cells that became long lived.
Numbers of labeled and unlabeled B cells in mutant mice are given in
parentheses as percentages of the numbers found in control mice (con-
trol 5 100%).
Figure 8. Development of T2 and mature B cells is blocked in mice
lacking the cytoplasmic tail of Ig-a. Spleen cells of mb1 Dc/Dc (left),
CD452/2 (center), and mb1 Dc/Dc-CD452/2  double-mutant (right)
mice were stained with Abs to CD21 and IgM. Flow cytometric profiles
are shown. Dead cells, which fail to exclude the dye propidium iodide,
were excluded from the analysis. 100,000 events were collected.84 B Cell Development in the Spleen
population present in the spleens of CD452/2 mice does
not develop (Fig. 8; compare CD452/2 and double mutant).
This indicates that a BCR-mediated signal is required for
the development and proliferation of T2 B cells in the spleens
of CD452/2 mice.
Primary Follicles of Mutant Mice Show a Normal Architecture.
To study splenic architecture in the mutant mice, we stained
spleen sections with Abs against MAdCAM-1, a mucosal
vascular addressin that is expressed on the cells lining the
marginal sinus in the spleen (33). B cells were labeled with
anti-IgM Abs (Fig. 9). In the spleen of the control mouse,
the primary follicle (F) is surrounded by a thin layer of
MAdCAM-1–positive endothelial cells (green; indicated by
arrows). MZ B cells (MZ) express high amounts of IgM
and encircle the follicle (F) outside of the marginal sinus.
Follicles of CD452/2 mice have a larger size but a normal
distribution of MZ and follicular B cells. MZ and follicular
B cells also have a normal distribution in the spleens of
CBA/N mice (34). CBA/N mice, however, have very
small lymphoid follicles. The normal distribution of B cells
in the spleens of mutant mice shows that their T2 B cells
can enter the follicle and that the MZ has a normal propor-
tion, in accordance with the normal fraction of these cells
in the spleen.
Discussion
The differentiation pathway from stem cell to mature B
lymphocyte can be divided into several stages, character-
ized by differentiation processes, proliferation phases, and
control steps. The progression of B cells along this pathway
is probably best understood assuming that it is governed by
the principle of conditional survival. In each developmental
stage, specific genetic programs are completed in discrete
environments. To progress from one stage to the next, the
cells have to meet specific requirements set by the new de-
velopmental stage and the new environment. In the early
phases of differentiation in the bone marrow, the ability to
productively rearrange the H and L chain genes is an essen-
tial requirement (35). The signaling function of the BCR
plays an equally important role (36). It has recently been
shown that the presence of the BCR is also indispensable
for the survival of mature B cells in the periphery (37). This
study suggests that the mere presence of the signaling com-
plex organized around the IgM and IgD molecules gener-
ates a tonic signal necessary for the survival of mature B cells.
It could not, however, address the question of whether this
minimal constitutive signal is also sufficient to induce the
differentiation of B cells recently generated in the bone
marrow into mature B cells.
Studies of B lymphocyte population dynamics have shown
that entry into the pool of the mature long-lived B cells is a
highly selective event. Only 1–3% of the B lymphocytes
leaving the bone marrow every day enter the pool; the re-
mainder of the newly generated B cells are eliminated (5,
11, 38). The requirements that B cells have to meet at the
time of selection into the long-lived pool and the site
where selection takes place are largely unknown. We show
here that selection into the mature pool is an active process
and takes place in the spleen. Two populations of splenic B
cells were identified as precursors for mature B cells, the T1
and the T2 B cells. Their development into mature B cells
requires defined qualitative and quantitative signals derived
from the BCR. We finally show that the induction of lon-
gevity and maturation requires different signaling pathways.
A Functional BCR Is Indispensable for the Progression from T1
to T2 and Mature B Cell Stage in the Spleen. In the spleen, we
have identified four different B cell populations by flow cy-
Figure 9. Primary follicles of mutant mice show normal architecture. Cryostatic sections of spleens from normal and mutant mice were stained with
TRITC-labeled goat anti–mouse IgM Abs. Anti–MAdCAM-1 Abs (from rats) were counterstained with FITC-labeled goat anti–rat Abs. Green and red
fluorescence was measured separately by confocal laser microscopy, and the pictures obtained were then overlaid (magnification 100). The arrow points
to the thin layer of MAdCAM-1–positive endothelial cells of the marginal sinus. F, follicle.85 Loder et al.
tometry: T1, T2, mature, and MZ B cells. Their phenotypes
are summarized in Table III. T1 B cells originate from the
bone marrow and can be detected in the marrow, blood,
and spleen but not in the lymph nodes (Fig. 1 A). Entry
into the lymph nodes depends on the expression of the
homing receptor l-selectin (CD62L) (26). In both mice
treated with anti–l-selectin Ab (MEL-14 Ab) (39) and
mice deficient for l-selectin (40), the number of B and T
cells is drastically reduced in the lymph nodes but is in-
creased in the spleen. Our observations are in accordance
with these reports: T1 B cells lack the expression of l-selec-
tin (Fig. 1 A) and home to the spleen, not to the lymph nodes.
They enter the spleen via the terminal arterioles of the red
pulp and marginal sinus (41). B cells that do not express
CD21 and l-selectin have recently been described as non-
recirculating B cells in the blood. This subset of B cells
only homed to the spleen and was excluded from the lym-
phatic recirculation pathway (42). These cells are probably
T1 B cells in transit from the bone marrow to the spleen.
In normal mice, T2 B cells are only found in the spleen.
Phenotypically, they appear to be an intermediate stage of
differentiation between the T1 and the mature B cell stage.
Like T1 B cells, they still express high amounts of the early
hematopoietic marker HSA (5) and the recently described
marker of immature B cells (43), recognized by the mAb
493 (our unpublished observations). Like mature B cells,
they express IgD, CD23, and l-selectin. T2 B cells appear
in an activated state in vivo: they are large, they express
B7-2 (not shown), and a significant fraction of them is in
the G2–M phase of the cell cycle (Table I).
MZ B cells are also found in the spleen, in a specialized
area that surrounds the white pulp outside the marginal si-
nus (44), and are phenotypically different from T1 and T2
B cells (Fig. 1, C and D). MZ B cells are nonrecirculating,
long-lived B cells (45).
To establish the ontogenetic order of appearance of T1,
T2, and mature B cells, we injected T1 B cells intrave-
nously into RAG-22/2 mice. T1 B cells developed into T2
and mature B cells 48 h after the injection into adult RAG-
22/2 mice (Fig. 2 B). This experiment demonstrates that
T1 B cells are the precursors of T2 and mature B cells but
does not establish the developmental relationship between
T2 and mature B cells. T2 and mature B cells could repre-
sent two independent, end-stage populations generated
from the T1 pool. The relatively immature phenotype of
T2 B cells and their exclusive presence in the spleen, the
only organ where T1 are also found, however, suggest an-
other possible scenario: T2 B cells may represent a devel-
opmental checkpoint between T1 and mature B cells. To
study the fate of T2 B cells, we transferred them into
RAG-22/2 mice. T2 B cells developed into mature B cells
in 24 h (Fig. 3). Our data shows that T2 B cells represent
an intermediate stage of development that feeds into the
mature pool. However, we cannot and will not exclude
the possibility that at least a fraction of the T1 B cells can
directly develop into mature B cells.
T1 and T2 B cells are found in different microenviron-
ments in the spleen. T1 B cells are located in the red pulp
and the outer PALS, whereas T2 and mature B cells are lo-
cated in the follicle (Fig. 4). The development of T2 and
mature B cells from T1 precursors and their specific local-
ization in different microenvironments in the spleen might
be influenced by the signaling capacity of the BCR. In-
deed, it was recently demonstrated that B cells deficient for
Syk, a tyrosine kinase that plays a fundamental role in BCR
signaling, migrate from the bone marrow to the spleen but
fail to enter the primary follicle and remain in the red pulp
and the PALS (46). In addition, it has been shown that en-
counter with antigen influences the migration of B cells
from the outer PALS to the follicle (47). It is therefore
likely that T1 B cells can enter the primary follicle only if
they received a signal in the outer PALS and became T2 B
cells. Because entrance into the primary follicles of the spleen
is impaired in B cells of mice deficient for the chemokine
BLR-1 (48), it is possible that B cells acquire the ability to
respond to BLR-1 at the T2 stage.
To analyze the role of the signaling capacity of the BCR
in this phase of development, we have studied mice with
genetic defects of signaling elements involved in the BCR
pathway. In mice lacking the cytoplasmic tail of Ig-a (mb1
Dc/Dc mice), the signaling function of the BCR is severely
impaired. The number of B cells in the bone marrow is re-
duced to 20% of normal (12). We show here that B cells in
the spleen are arrested at the T1 stage of development (Fig.
8). These findings demonstrate that the final steps of B cell
development in the spleen, from T1 to T2, mature, and MZ
B cells require a functional BCR. The fact that the early
stages of B cell development are impaired in the bone mar-
row of mb1 Dc/Dc mice, whereas the late stages are com-
pletely abolished in the spleen, may reflect a more strict re-
quirement for a perfectly functional BCR in the final
phases of differentiation.
In mice deficient for the tyrosine phosphatase CD45, B
cells with a proper mature phenotype are missing, whereas
the T2 population is six- to eightfold larger than in normal
mice (Table II). T2 B cells proliferate in the spleens of
CD452/2 mice. At least 30% of them are in the G2–M phase
of the cell cycle. Surprisingly, also in normal and CBA/N
mice, 15–20% of the T2 B cells are in the G2–M phase (Ta-
Table III. Phenotypic Description and Tissue Distribution of 
Immature, T1, T2, Mature, and MZ B Cells
IMM T1 T2 M MZ
IgM 1 111 111 1 111
IgD 2 2 111 111 2
CD21 2 2 111 11 111
CD23 2 2 11 11 2
Location BM BM, B, S S BM, B, S, LN S
Expression of the indicated markers is given as negative (2), weakly
positive (1), positive (11), and strongly positive (111). The location
where the various cell types are found is also indicated: bone marrow
(BM), blood (B), spleen (S), and lymph nodes (LN). IMM, immature.86 B Cell Development in the Spleen
ble I). In contrast, both T1 and mature B cells are in the
G0–G1 phase. This result suggests that the BCR-mediated
activation event responsible for the progression from the T1
to T2 stage results in the proliferation of a large fraction of
the T2 cells. Proliferation is deregulated in the absence of
CD45. When CD452/2 mice were backcrossed to mb1
Dc/Dc mice, the development of T2 B cells was completely
blocked (Fig. 8). Therefore, a BCR-mediated signal is nec-
essary for the development of T1 to T2 B cells in the spleen
and induces a proliferative response at this stage.
Given the large number of short-lived B cells in CD452/2
mice, a low recruitment rate into the long-lived pool (2%
as compared with 16% in normal mice) still ensures an al-
most normal influx into the long-lived pool (Table II). The
low recruitment rate may reflect a limited supply of re-
sources necessary to support the survival of B cells (49).
The CD45 tyrosine phosphatase positively regulates and
amplifies BCR-derived signals. The tyrosine phosphatase
SHP-1 has the opposite function and reduces and termi-
nates signals generated by the BCR (50). Development of
mature B cells was rescued when CD452/2 mice were
back-crossed to motheaten mice, which lack SHP-1 activ-
ity (51). Also, the deletion of CD22 (52), which recruits
SHP-1 to the BCR and negatively regulates B cell signal-
ing, rescues the development of mature B cells in CD452/2
mice (Wardemann, H., F. Loder, M.C. Lamers, and R. Car-
setti, manuscript in preparation). Signal strength is therefore
an essential factor in determining the fate of B cells in the
late phases of development from T1 to mature B cells. A
strong signal is necessary for the development of mature B
cells, but a weak signal is sufficient for the development of
T2 and MZ B cells.
More complex is the interpretation of the CBA/N de-
fect. Also in this case, T2 and MZ B cells develop but long-
lived mature B cells are absent. The effect of Btk on B cell
survival can only partially explain the defect. The overex-
pression of bcl-2 (53), which belongs to a family of pro-
teins that inhibits apoptosis and prolongs B cell life span,
leads to the increase of T2 B cells but does not rescue the
development of mature B cells. It is, therefore, likely that
Btk plays a dual role in B cells: it controls their life span and
also regulates their final differentiation to mature B cells.
Accordingly, several downstream effectors and partners of
Btk have been identified, including members of the bcl-2
family but also elements of the mitogen-activated protein
(MAP) kinase pathway (20).
Little is known about the nature of events downstream
of the BCR necessary for B cell maturation. We have evi-
dence that the MAP kinase pathway plays an important
role in these processes. For instance, T2 B cells become
mature B cells in vitro upon transient and strong activation
of the MAP kinase pathway, whereas mice that are trans-
genic for a dominant-negative form of MAP kinase/extra-
cellular regulated kinase (MEK) show a developmental ar-
rest at the T2 stage (Carsetti, R., personal observation).
The high expression of CD21 on T2 B cells could play an
important role in this process. CD21 forms a complex with
the CD19 coreceptor. Cross-linking of the BCR with the
CD21–CD19 complex strongly activates the MAP kinase
pathway (54) and may result in the generation of mature
from T2 B cells. T2 B cells that do not find their ligands
may remain in the spleen as T2 B cells. A summary of our
view of the developmental pathways of B cells in the
spleen is given in Fig. 10. 
Implications. Our data demonstrate that two factors reg-
ulate the development of T1 into T2 and mature B cells:
the signaling function of the BCR and the microenviron-
ment of the adult spleen. In a simplified model, strength
and duration of BCR-mediated signals determine the out-
come of antigen receptor–induced B cell activation: death
or survival, proliferation, or differentiation. Three factors
regulate signal strength: the antigen, the antigen receptor,
and the signal transduction machinery. We have shown
that mutations affecting the components of the BCR signal
transduction cascade severely influence the late stages of B
cell development in the spleen. In normal mice, the choice
between proliferation and differentiation might depend
mostly on the structure of the ligand, which regulates the
extent of cross-linking, and on the affinity of the BCR for
this ligand, which also affects the intensity of the signal. Ex-
periments with transgenic mice have clearly shown that B
cells that have a high affinity for self-antigens, and therefore
Figure 10. Proposed developmental pathways of B cells in the spleen.
The B cell subpopulations described in this paper are depicted as they
would appear in a flow cytometric profile after staining with anti-IgM and
anti-CD21 Abs. T1 B cells recently immigrated from the bone marrow
develop into T2 B cells if they receive a BCR-mediated signal. This signal
is insufficient in Ig-a– and Syk-deficient mice. Progression of T2 B cells
into the mature long-lived pool (M) is blocked in mice with qualitative
and quantitative defects in BCR signaling function, as in Btk-, Vav-,
Lyn-, and CD452/2 mice, and in transgenic mice with a dominant-nega-
tive form of MEK (DN-MEK), which is only expressed in B cells. MZ B
cells are thought to derive from mature B cells but are also found in mice
with a developmental arrest at the T2 stage, leaving open the possibility
that they can also be derived from T2 B cells. It is presently unclear
whether T1 B cells can directly differentiate into mature cells in the spleen.
Solid arrows, major pathways; broken arrows, possible pathways; ^, path-
way blocked; *inferred from the literature; **our unpublished data.87 Loder et al.
receive a strong signal upon binding, are deleted. Positive
selection in the mature pool may happen at a much lower
signaling threshold, at a level where the quality and com-
position of the BCR signal transduction apparatus is of fun-
damental importance.
This model predicts that B cells expressing certain V re-
gion specificities would be selected only into the T2 or MZ
pools and never into the mature pool and vice versa. Indeed,
previous findings are compatible with this view. In mice,
where the rearranged T15 VH region gene was introduced
in its natural location, 59 of the Ig intron enhancer, all B cells
expressed the transgenic VH region in their Abs. Splenic B
cells had the phenotype of T2 B cells, and the mature pop-
ulation was absent (55). In a transgenic mouse model, it has
recently been shown that B cells expressing a multireactive
IgM transgene derived from fetal liver B cells are selected
into the MZ (56) but do not become mature B cells.
What is the ligand that drives the B cells during the last
stages of differentiation? We do not have an answer to this
important question. In germ-free mice, the number of ma-
ture B cells is strongly reduced, whereas the number of T2
B cells is normal (data not shown). T cells are not necessary
for the development of T2 and mature B cells, because
both populations are present in mice unable to generate T
cells (data not shown). Large, activated B cells have been
previously described in the spleens of normal mice and
were called naturally activated B cells. They are probably
generated by the low-affinity interaction with autoantigens.
Naturally activated B cells are thought play an important
role in the construction of the B cell repertoire and secrete
the natural antibodies found in the sera of mice and humans
(57, 58). Natural Abs play a role in the defence against
common pathogens and may represent a linkage between
innate and adaptive immunity (59). T2 B cells might be
identical to this population. Alternatively, T2 B cells could
have a function in the first-line, rapid, and thymus-inde-
pendent defense against infectious agents. Recruitment of
T2 B cells in this type of immune response might be facili-
tated by the preactivated state of this cell type by the high
density of the BCR and complement receptors. In agree-
ment with this possibility, encapsulated bacteria, which
induce a rapid thymus-independent immune response in
normal individuals, cause a life-threatening disease in sple-
nectomized and hyposplenic patients. This acute form of
sepsis, known as OPSI (overwhelming post-splenectomy in-
fection), frequently results in the death of the patient (60).
The identification of two new stages of B cell develop-
ment in the spleen allows a better definition of the pheno-
type of mice with defects of the BCR signaling pathway.
Indeed, a survey of the published data suggests that B cell
development may be blocked at the T1 stage in Syk-defi-
cient mice (46) but at the T2 stage in both Lyn (61, 62) and
Vav mutant (63, 64) mice (Fig. 10). The role of the spleen
in the development of T2 and mature B cells can be stud-
ied thanks to the availability of mice lacking spleens or hav-
ing severely altered splenic architecture.
Finally, preliminary experiments have shown that T2 B
cells are also present in the human spleen and, under cer-
tain pathophysiological conditions, also outside of the
spleen. Our study should help provide a better understand-
ing of the rules and signals that regulate B cell survival, dif-
ferentiation, and activation in health and disease in mice
and in humans.
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